Investors

Latest News

Expedeon AG adds five new Alexa Fluor labels to its Lightning-Link antibody labeling kit range

August 14th, 2018

Heidelberg, Germany and Cambridge, UK, 14 August 2018 – Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced the introduction of five new Alexa Fluor® labels to its range of Lightning-Link® antibody labelling kits. The addition further expands Expedeon’s range of labels, offering customers increased choice and flexibility for common fluorescence detection based applications….

View

SYGNIS introduces 2view unique Western blot detection technology

May 9th, 2018

Heidelberg, Germany and Cambridge, UK, 09 May 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the introduction of 2view™, a unique detection method optimised for Western blotting, under its Expedeon brand name. 2view™ is an innovative double labeled secondary antibody that enables extended detection within the widely used Western blot application….

View

SYGNIS completes acquisition of TGR Biosciences

May 8th, 2018

Heidelberg, Germany and Cambridge, UK, 08 May 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the completion of the acquisition of TGR Biosciences (TGR), the Australian research reagents company. TGR and its highly complementary technologies and products along with its strong customer base will significantly contribute to the overall performance of…

View

SYGNIS announces completion of Sales and Marketing team restructuring to support continued strong revenue growth

March 15th, 2018

Heidelberg, Germany and Cambridge, UK, 15 March 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), today announced the restructuring of its sales and marketing team to drive continued strong revenue growth. A direct sales and distribution team focused on product sales has been formed while a business development team will focus on partnering…

View

SYGNIS completes integration of acquired companies’ products and services under Expedeon brand name

March 6th, 2018

Heidelberg, Germany and Cambridge, UK, 6 March 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), today announced its subsidiaries Innova Biosciences, Expedeon Holdings, and C.B.S. Scientific have united as Expedeon, effective 1 March 2018. The corporate rebranding follows the latest acquisition of Innova Biosciences by SYGNIS AG in June 2017. SYGNIS AG will…

View

SYGNIS AG extends OEM agreement with leading global research tools provider

February 21st, 2018

Heidelberg, Germany and Cambridge, UK, 21 February 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has signed an extended OEM agreement with one of its key strategic partners, a leading global research tools provider to the life science industry….

View

SYGNIS AG Installs Scalable Production Capability for Lightning-Link Antibody Conjugation Technology

January 16th, 2018

Heidelberg, Germany and Cambridge, UK, 16 January 2018: SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has extended the manufacturing capability for its Lightning-Link® technology, currently marketed under the Expedeon brand, to support scalability and bulk production of antibodies. Lightning-Link is…

View

SYGNIS AG launches TruePrime apoptotic cell free DNA amplification kit for the liquid biopsy market

December 6th, 2017

Heidelberg, Germany and Cambridge, UK, 06 December 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced the launch of its TruePrime™ apoptotic cell free DNA amplification kit, under the Expedeon brand. The kit enables accurate DNA amplification using cell free DNA…

View

SYGNIS AG signs supply agreement with US Biological for the Lightning-Link® antibody labelling technology

November 28th, 2017

Heidelberg, Germany and Cambridge, UK, 28 November 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has signed a supply agreement with US Biological, Salem, MA, USA, for its Innova Lightning-Link® technology. Heikki Lanckriet, CEO and CSO of SYGNIS AG,…

View

SYGNIS AG partners with Abingdon Health to provide full service custom lateral flow assay design and supply

November 7th, 2017

  Cambridge, UK, 07 November 2017: SYGNIS AG, under the Expedeon (Innova) brand name, a specialist provider of bioconjugation products and services, today announced it has established a partnership with Abingdon Health Ltd (“Abingdon”), which will enable Innova to provide its customers with full lateral flow assay development services as well as establishing Innova as…

View

SYGNIS AG announces the launch of the Universal Lateral Flow Assay Kit and associated patent filing

October 25th, 2017

Enables fast and easy development of customized sandwich lateral flow assays Cambridge, UK, 25 October 2017: SYGNIS AG today announced the launch of its Universal Lateral Flow Assay (LFA) kit, the latest addition to its expanding range of lateral flow assay products and services which are being commercialized under the Expedeon brand name. The novel…

View

Move forms part of integration into SYGNIS Group

October 20th, 2017

Madrid, Spain and Heidelberg, Germany, 18 October 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the completion of the relocation of its subsidiary company, Expedeon, into the Company’s existing facilities in Cambridge, UK. The relocation follows the recent acquisition of Expedeon by SYGNIS AG, and the continued integration of Innova within…

View